Sequencing Strategies in Prostate Cancer

Optimal Sequencing Explored for Enzalutamide and Abiraterone in mCRPC

April 21, 2016

Clinical Articles

Within the past 5 years, several agents have become available for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on survival benefits observed in randomized clinical trials

Analysis of Real-World Data for Next-Generation Antiandrogen Therapies

April 21, 2016

Clinical Articles

Since 2010, several novel therapies have been approved for use in metastatic castration-resistant prostate cancer (mCRPC). Although they have expanded the therapeutic repertoire for clinicians, they also bring a new set of challenges for the optimal clinical management of patients with mCRPC.

Experts Discuss Treatment Sequencing Strategies in CRPC

April 21, 2016

Clinical Articles

As the treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) continues to evolve, optimal strategies are becoming more apparent on how to best sequence the multitude of novel therapies that have been approved in the past decade.

Steroid Use With Abiraterone Offers Multidimensional Benefits to Patients With mCRPC

April 21, 2016

Clinical Articles

For decades, the standard of care for men with advanced prostate cancer has been the depletion or inhibition of androgens. While androgen-deprivation therapy (ADT) often results in temporary tumor regression or symptom relief in some patients, disease progression ultimately occurs over time.